Commentary: FGF21 holds promises for treating obesity-related insulin resistance and hepatosteatosis

Endocrinology

Volumn 155, Issue 2, 2014, Pages 343-346

  Alisi, Anna ^a   Panera, Nadia ^a   Nobili, Valerio ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; MYOSIN; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN MDM2; STAT3 PROTEIN; UBIQUITIN PROTEIN LIGASE;

FATTY LIVER; HUMAN; INSULIN RESISTANCE; MOLECULAR MECHANICS; NOTE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

FATTY LIVER; FIBROBLAST GROWTH FACTORS; HUMANS; INSULIN RESISTANCE; OBESITY;

EID: 84893157935     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1828     Document Type: Note

References (29)

1. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta. 2000;1492: 203-206.
2. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115: 1627-1635.
3. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor 21. Endocrinology. 2007;148: 774-781.
4. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57: 1246-1253.
5. Ito S, Kinoshita S, Shiraishi N, et al. Molecular cloning and expression analyses of mouse βklotho, which encodes a novel Klotho family protein. Mech Dev. 2000;98: 115-119.
6. Fon Tacer K, Bookout AL, Ding X, et al. Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol. 2010;24: 2050-2064.
7. Wente W, Efanov AM, Brenner M, et al. Fibroblast growth factor- 21 improves pancreatic β-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes. 2006;55: 2470-2478.
8. Lin Z, Tian H, Lam KS, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013;17: 779-789.
9. Muise ES, Souza S, Chi A, et al. Downstream signaling pathways in mouse adipose tissues following acute in vivo administration of fibroblast growth factor 21. PLoS One. 2013;8:e73011.
10. Li H, Zhang J, Jia W. Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology. Front Med. 2013;7: 25-30.
11. Mraz M, Bartlova M, Lacinova Z, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf). 2009;71: 369-375.
12. Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010;139: 456-463.
13. Habegger KM, Stemmer K, Cheng C, et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes. 2013;62: 1453-1463.
14. Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013;18: 333-340.
15. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology. 2009;150: 4931-4940.
16. Feingold KR, Grunfeld C, Heuer JG, et al. FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis. Endocrinology. 2012;153: 2689-2700.
17. Kim KH, Jeong YT, Oh H, et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med. 2013;19: 83-92.
18. Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin- ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013;17: 790-797.
19. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451: 1069-1075.
20. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59: 2781-2789.
21. Ding X, Boney-Montoya J, Owen BM, et al.βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 2012;16: 387-393.
22. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 2007;282: 26687-26695.
23. Hale C, Chen MM, Stanislaus S, et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology. 2012;153: 69-80.
24. Moschen AR, Wieser V, Tilg H. Adiponectin: key player in the adipose tissue-liver crosstalk. Curr Med Chem. 2012;19: 5467-5473.
25. Camporez JP, Jornayvaz FR, Petersen MC, et al. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology. 2013;154: 3099-3109.
26. Morris-Stiff G, Feldstein AE. Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice. J Hepatol. 2010;53: 795-796.
27. Shen J, Chan HL, Wong GL, et al. Non-invasive diagnosis of nonalcoholic steatohepatitis by combined serum biomarkers. J Hepatol. 2012;56: 1363-1370.
28. Alisi A, Ceccarelli S, Panera N, et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. PLoS One. 2013;8:e67160.
29. Planavila A, Redondo I, Hondares E, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun. 2013;4:2019.